Find Clinical Trials

Inclusion Criteria: * English or Spanish speaking * Less than 30 gestational weeks Exclusion Criteria: * None

Inclusion Criteria: * Participant must be 12 to 17 years of age (inclusive), at the time of signing the informed consent/assent. * Participants who have a diagnosis of asthma as defined by the National Institutes of Health \[NIH, 2020\] at least 1 year prior to Visit 0. * Participants who have required daily Inhaled corticosteroids (ICS)/ Long-Acting Beta2-Agonist (LABA) treatment for at least 12 weeks prior to Visit 0 with no changes to maintenance asthma medications during the 6 weeks immediately prior to Visit 0 (including no changes to a stable total ICS dose of \>250 to \<=500 microgram (mcg)/day fluticasone propionate, or equivalent). * In the 1 year prior to Visit 1: A documented healthcare contact for acute asthma symptoms; OR A documented temporary change in asthma therapy for acute asthma symptoms, according to a prespecified asthma action plan (or equivalent). * Participants with inadequately controlled asthma (ACQ-6 score ≥1.5) at Visit 1, despite ICS/LABA maintenance therapy. * A best pre-bronchodilator FEV1 \>40% to \<=90% of the predicted normal value and a ≥12% increase in FEV1 with albuterol/salbutamol at Visit 1. Predicted values will be based on the European Respiratory Society (ERS) Global Lung Function Initiative. Exclusion Criteria: * Chest X-ray documented pneumonia in the 6 weeks prior to Visit 1. * Any asthma exacerbation requiring a change in maintenance asthma therapy and/or the use of systemic corticosteroids for at least 3 days in the 6 weeks prior to Visit 1. (Participants requiring a temporary change in asthma therapy (e.g., oral corticosteroids or increased dose of ICS) to treat an exacerbation in the 6 weeks prior to Visit 1 are not explicitly excluded at Visit 1 provided that, at the Investigator's discretion, the participant's condition is stable after they have resumed their pre-exacerbation maintenance asthma therapy (without modification), returned to their baseline asthma status and they are considered appropriate for enrollment into this study of up to 6 months duration) * History of Life-threatening Asthma * Participants with current evidence of active pulmonary diseases or abnormalities other than asthma (e.g., pneumonia, active tuberculosis, significant bronchiectasis, etc.). * Current smokers and users of other inhaled products for recreation with or without nicotine (defined as participants who use cigarettes, e-cigarettes, other/vaping-related devices, cigars or pipe tobacco\]) within 12 months prior to Visit 1.

Inclusion Criteria: * Female subjects; * Age between 18 and 88 years; * Detection of microcalcifications on clinical and screening mammography with or without indication for histological assessment by biopsy; * Subjects who agree to participate in the study by signing and dating the Informed Consent form Exclusion Criteria: * Personal history of breast cancer

Inclusion Criteria: 1. Patients who voluntarily participate in the study, completely understand the study, and voluntarily sign the informed consent form (ICF). 2. Female, ≥ 18 and ≤ 75 years of age at the time of signing the ICF. 3. ECOG（Eastern Cooperative Oncology Group） performance status 0 or 1. 4. Life expectancy ≥ 3 months. 5. Patients with locally advanced or metastatic breast cancer who are unable to receive radical surgeries/other local therapies, with hormone receptor positive and human epidermal growth factor receptor 2 negative confirmed by tumor histopathology and molecular pathology. 6. No previous systemetic therapy for locally advanced or metastatic diseases that cannot receive radical surgeries/other local therapies. 7. At least one measurable lesion as per the Response Evaluation Criteria in Solid Tumors. 8. Postmenopausal or premenopausal/perimenopausal female patients. Premenopausal or perimenopausal women should consent to receive goserelin therapy during the study. 9. Laboratory test results before randomization meet the relevant requirements for organ function. Exclusion Criteria: 1. Prior treatment with any CDK4/6 （Cyclin dependent kinase）inhibitor. 2. Inflammatory breast cancer. 3. Patients unsuitable for endocrine therapy at the investigator's discretion. 4. History of other malignancies within 5 years prior to the start of study treatment. 5. Patients with known central nervous system metastases. 6. Taking anti-tumor traditional Chinese medicines at the time of signing the ICF. 7. Having undergone a surgery within 28 days prior to the start of study treatment, and hasn't yet recovered from adverse reactions of the surgery. 8. History of myocardial infarction, unstable angina pectoris, severe arrhythmia, and symptomatic congestive heart failure before the start of study treatment; NYHA( New York Heart Association) Class ≥II; QTcF≥ 470 ms; LVEF(Left Ventricular Ejection Fractions)≤ 50%. 9. History of ischemic stroke or severe thromboembolic disease before the start of study treatment. 10. Being receiving potent CYP3A4 inhibitors or inducers at the time of signing the ICF. 11. Hepatitis B surface antigen positive and HBV(Hepatitis B Virus) DNA \> 2,000 IU/mL or 104 copies/mL; HCV(hepatitis C virus) antibody positive and HCV RNA positive; or known HIV infection. 12. Patients who participated in a clinical trial and received other investigational drugs within 30 days before the start of study treatment. 13. History of severe anaphylactic diseases, history of severe drug allergy, or known allergy to any ingredient of the investigational product. 14. Presence of diseases or conditions that may impact drug administration or gastrointestinal absorption before the start of study treatment, in the opinion of the investigator, makes them an unsuitable candidate for the study. 15. Uncontrolled infections within 2 weeks before the start of study treatment, in the opinion of the investigator, makes them an unsuitable candidate for the study. 16. Pregnant or lactating women. 17. Known history of substance abuse, excessive drinking, or illegal drug addiction; history of confirmed neurological or mental disorders. 18. Presence of other diseases judged by the investigator that the risks of receiving the study treatment outweigh its benefits, or any other reason for which patients are ineligible for the study as assessed by the investigator and the sponsor.

Inclusion Criteria: * Female patients aged ≥ 20 years old at the time of informed consent. * Patient has a histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive breast cancer based on the most recently analyzed tissue sample and all tested by local laboratory. with estrogen receptor positive (\>10%) on IHC staining and HER2 negative (IHC 0+/1+, or IHC 2+ plus FISH negative) * Stage II to III * With adequate organ function * ECOG 0-1 Exclusion Criteria: * Pregnant or nursing (lactating) women * Women of child-bearing potential unless using highly effective methods of contraception during study drug dosing and for 12 months post-dosing * Patients with active systemic infections or known to have AIDS or to test positive for HIV antibody at Screening * Any other disease or condition that could interfere with participation in the study according to the study protocol, or with the ability of the patients to cooperate and comply with the study procedures.

Only individuals who complete 12 weeks of the blinded Depressed MIND trial will be eligible for enrollment. Eligibility criteria for the blinded phase includes: Inclusion Criteria: 1. Age ≥ 60 years; 2. Diagnosis of major depressive disorder, single or recurrent episode (DSM5); 3. On a stable therapeutic dose of an allowed SSRI or SNRI for at least 8 weeks; 4. Severity: Montgomery-Asberg Depression Rating Scale (MADRS) score ≥ 15; 5. Cognition: Mini-Mental State Examination (MMSE) score ≥ 24; 6. Fluent in English Exclusion Criteria: 1. Other Axis I psychiatric disorders, except for generalized anxiety disorder (GAD) or social phobia symptoms occurring in a depressive episode or diagnosis of an attentional disorder, such as Attention Deficit Hyperactivity Disorder (ADHD); 2. Use of other augmentation medication treatments for depression, or ADHD e.g., stimulant medications,, e.g., adjunctive bupropion or other augmenting agents, that the participant does not want to stop, although short-acting sedatives are allowed (see below); 3. Any use of tobacco or nicotine in the last year; 4. Living with a smoker or regular exposure to secondhand smoke; 5. History of alcohol use disorder or substance use disorder of moderate or greater severity (endorsing 4 or more of the 12 criteria) in the last 12 months; 6. Acute suicidality; 7. Acute grief (\<1 month); 8. Current or past psychosis; 9. Primary neurological disorder, including dementia, stroke, epilepsy, etc.; 10. MRI contraindication; 11. Electroconvulsive therapy or transcranial magnetic stimulation in last 2 months; 12. Current or planned psychotherapy; 13. Allergy or hypersensitivity to nicotine patches; 14. In the last 4 weeks, regular use of drugs with central cholinergic or anticholinergic properties or moderate / severe CYP2A6 inhibitors /inducers.

Inclusion Criteria: 1. Participant is a male or female 0 to \< 8 years of age, inclusive, at Day 1 2. Participant has Stage 2 T1D (two T1D-related autoantibodies and dysglycemia) Exclusion Criteria: 1. Participant has any autoimmune disease other than T1D with the exception of stable thyroid or celiac disease 2. Has an active infection and/or fever 3. Has a history of or serologic evidence at screening of current or past infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV). 4. Has any condition that, in the opinion of the Investigator, would interfere with the study conduct or the safety of the participant.

Inclusion Criteria: 1. Age ≥ 60 years; 2. diagnosis of major depressive disorder, single or recurrent episode (DSM5); 3. On a stable therapeutic dose of an allowed SSRI or SNRI for at least 6 weeks; 4. severity: at least mild active depression symptoms, defined as MADRS ≥ 15; 5. cognition: MMSE ≥ 24; 6. fluent in English Exclusion Criteria: 1. Other Axis I psychiatric disorders, except for generalized anxiety disorder (GAD) or social phobia symptoms occurring in a depressive episode or diagnosis of an attentional disorder, such as Attention Deficit Hyperactivity Disorder (ADHD); 2. Use of other augmentation medication treatments for depression or ADHD e.g., stimulant medications (e.g., adjunctive bupropion or other augmenting agents) that the participant does not want to stop, although short-acting sedatives are allowed; 3. Any use of tobacco or nicotine in the last year. 4. Living with a smoker or regular exposure to secondhand smoke. 5. History of alcohol use disorder or substance use disorder of moderate or greater severity (endorsing 4 or more of the 12 criteria) in the last 12 months. 6. Acute suicidality. 7. Acute grief (\<1 month); 8. Current or past psychosis. 9. Primary central nervous system neurological disorder, including dementia, stroke, epilepsy, etc.; 10. Presence of unstable medical illness requiring urgent treatment or intervention; 11. MRI contraindication. 12. Electroconvulsive therapy or transcranial magnetic stimulation in last 2 months; 13. Current or planned psychotherapy where the potential participant does not want to pause therapy for the duration of the study; 14. Allergy or hypersensitivity to nicotine patches; 15. In the last 4 weeks, regular use of drugs with central cholinergic or anticholinergic properties or moderate / severe CYP2A6 inhibitors /inducers

Inclusion Criteria: * Age 40 or older * Primary diagnosis of an anxiety or depressive disorder as determined by a clinical severity rating score of 4 or greater on the Anxiety Disorders Interview Schedule (ADIS). * Mini Mental Status Exam (MMSE) no more than 1 SD below the mean score for patient's age and education. If the remote version of the MMSE is used (e.g. during an evaluation on Zoom), the remote MMSE score will be converted to a standard MMSE score. * Access to an Apple iPhone, iPad, or Android device. Exclusion Criteria: * Lifetime diagnosis of a bipolar or psychotic disorder. * Currently in cognitive behavior therapy. * Change in dose of a psychiatric medication in the past 12 weeks. * Initiation of psychotherapy in the past 12 weeks. * Intent or plan to attempt suicide.

Inclusion Criteria: * Age between 6 and 16 years * FEV1 \> 60% * Child referred to the pulmonary function test laboratory for a non-specific bronchial hyperactivity test with methacholine * Child under treatment with inhaled corticosteroids stopped for at least 3 weeks * Oral consent from the child and at least one of the legal representatives * Child affiliated or benefiting from a social security plan Exclusion Criteria: * Use of a short-acting beta-adrenergic bronchodilator within the last 6 hours or anticholinergic bronchodilator within the last 12 hours * Use of a long-acting beta-adrenergic bronchodilator (licensed for use in children) in the past 36 hours * Upper or lower respiratory tract infections within 3 weeks prior to inclusion * Epilepsy under treatment * Subject's participation in another interventional study that may alter respiratory function * Patient unable to give consent, vulnerable

Inclusion Criteria: * Female subjects, 20 years age or older, suffered from unilateral breast cancer with ipsilateral lumpectomy or mastectomy and lymph node dissection (sentinel biopsy or axillary dissection) * Stage I or II unilateral secondary upper extremity lymphedema(as defined by the International Society of Lymphology) * Girth≥ 2 cm circumferential difference compared with the uninvolved upper extremity at any 4 cm segment * Able to commit to a long-term follow-up schedule Exclusion Criteria: * Metastatic cancer(stage IV) * Pregnancy * Presence of other extremity lymphedema (primary or secondary) * History of deep vein thrombosis * Pacemaker * Artificial joints, implant or tattoo(area≥4 cm2) at the involved upper extremity * Previous treatment with low-level laser therapy (within 3 months) * Body mass index (BMI) \> 35 (morbid obesity) * High bleeding tendency(hemophilia) * Receiving long-term steroid treatment (oral or systemic)

Inclusion Criteria: * 18 years of age or older * Diagnosed with advanced stage (III, IV) ovarian (ovarian, fallopian tube or primary peritoneal) or metastatic breast cancer \[do not need to be newly diagnosed\] * Currently receiving any type of therapy for their cancer \[can be front-line, maintenance therapy, or treatment for recurrence\] * Able to complete study tasks in English * Able to provide voluntary informed consent * Own an Android or iOS smartphone on which the operating system is version 9.0 or higher for Android or 10.0 higher for iOS; or willing to use a researcher-provided smartphone Exclusion Criteria: * Those who are currently incarcerated * Have opted out of research contact

Inclusion Criteria: * Age 18 and older with binocular vision * Able to provide informed consent * Patient is a healthy control OR is recommended for glaucoma assessment OR diagnosed with moderate to severe glaucoma in at least one eye as determined by Hodapp Anderson Criteria Exclusion Criteria: * The subject has significant media opacity (e.g., a visually significant cataract or significant corneal scar) * The subject has previous ocular surgery other than uncomplicated cataract extraction, laser trabeculoplasty (ALT or SLT), or YAG capsulotomy * The subject has prior ocular disease other than glaucoma * The subject has anatomically narrow angles or a prior adverse reaction to administration of Tropicamide or fluorescein dye * The subject has more than 15 diopters of refractive error * The subject is a female who is pregnant or nursing * The subject has diabetes mellitus

Inclusion Criteria: 1. Adult women and men ≥ 18 years of age. 2. Histologically confirmed HER2-positive breast cancer: o Documented HER2 overexpression by local laboratory (IHC 3+ or FISH or CISH positive on diagnostic breast biopsy). 3. Newly diagnosed breast cancer, planned for neoadjuvant therapy prior to surgery. 4. Stages 2-3 breast cancer. 5. Patients should not have received any prior therapy for breast cancer. 6. Patients must be willing to undergo mandatory tumour biopsy at Cycle 2 Day 14 (+/- 4 days) and (if applicable, refer to section 9.5 Tomosynthesis-Guided Core Biopsies sub-study and Table 8-2) before surgery . 7. ECOG performance status 0-1. 8. Availability of archival tumour biopsy tissue at screening. 9. Left ventricular ejection fraction (LVEF) ≥ 50%, as determined by ECHO or MUGA. 10. Adequate laboratory values collected no more than 14 days before registration. All parameters must meet the inclusion criteria on the same day, and must be the most recent results available: * Absolute neutrophil count (ANC) ≥ 1.5 x 109/L (granulocyte-colony stimulating factor administration is not allowed within 1 week prior to C1D1) * Platelet count ≥ 100 x 109/L (Platelet transfusion is not allowed within 1 week prior to C1D1) * Haemoglobin ≥ 9.0 g/dL. NOTE: Participants requiring ongoing transfusions or growth factor support to maintain haemoglobin ≥9.0 g/dL are not eligible (Red blood cell transfusion is not allowed within 1 week prior to C1D1). * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × upper limit of normal (ULN) * Total bilirubin ≤ 1.5xULN or \< 3×ULN in the presence of documented Gilbert's syndrome (unconjugated hyperbilirubinemia) * Serum albumin ≥ 25 g/L * Creatinine clearance (CrCL) ≥ 30ml/min as determined by Cockcroft Gault (using actual body weight) (refer to Appendix C). * Prothrombin time and either partial thromboplastin or activated partial thromboplastin time ≤ 1.5 × ULN. 11. Evidence of post-menopausal status or negative serum pregnancy test for females of childbearing potential who are sexually active with a non-sterilized male partner. For women of childbearing potential, a negative result for serum pregnancy test must be available at the screening visit. Women of childbearing potential are defined as those who are not surgically sterile (i.e. underwent bilateral salpingectomy, bilateral oophorectomy, or complete hysterectomy) or post-menopausal. Postmenopausal women defined as: i. Women aged \<50 years will be considered post-menopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels in the post-menopausal range for the site. ii. Women aged ≥50 years will be considered post-menopausal if they have been amenorrhoeic for 12 months or more following cessation of all exogenous hormonal treatments. iii. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods outlined for women of child-bearing potential if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to registration. For most forms of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method. 12. Women of childbearing potential must agree to use a highly effective method of contraception according to current HMA CTFG guideline when sexually active. This applies from signing of the informed consent form until at least 7 months after the last IMP administration. The investigator or a designated associate is required to advise the patient how to achieve an adequate birth control. Highly effective contraception is defined in the study as methods that achieve a failure rate of less than 1% per year when used consistently and correctly. Such methods include: i. Combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal). ii. Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable and implantable). iii. Intrauterine device (IUD). iv. Intrauterine hormone-releasing system (IUS). v. Bilateral tubal occlusion. vi. Successfully vasectomised partner. vii. Sexual abstinence. 13. Non-sterilized male patients who are sexually active with a female partner of childbearing potential must use a condom with spermicide from screening to 4 months after the final dose of IMP. Complete heterosexual abstinence for the duration of the study and drug washout period is an acceptable contraceptive method if it is in line with the patient's usual lifestyle (consideration must be made to the duration of the clinical trial); however, periodic or occasional abstinence, the rhythm method, and the withdrawal method are not acceptable. It is strongly recommended for the female partners of a male patient to also use at least one highly effective method of contraception throughout this period. In addition, male patients should refrain from fathering a child, or freezing or donating sperm from the time of registration, throughout the study and for 4 months after the last dose of IMP. Preservation of sperm should be considered prior to enrollment in this study. 14. Female patients must not donate, or retrieve for their own use, ova from the time of registration and throughout the study treatment period, and for at least 7 months after the final IMP administration. They should refrain from breastfeeding throughout this time. Preservation of ova may be considered prior to enrollment in this study. Exclusion Criteria: 1. Known metastatic or stage 4 breast cancer. 2. Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months). Myocardial infarction (MI) less than 6 months before registration, symptomatic congestive heart failure (CHF) (New York Heart Association Class II to IV). Patients with troponin levels above ULN at screening and without any myocardial related symptoms, should have a cardiologic consultation before enrollment to rule out MI. 3. Corrected QT interval (QTcF) prolongation to \>470 msec (females) or \>450 msec (males) based on the screening 12-lead ECG. 4. Uncontrolled arterial hypertension despite optimal medical management (per investigator's opinion). 5. Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 3 months before registration. 6. Non-healing wound, ulcer, or bone fracture. 7. Active, clinically serious infections \> CTCAE Grade 2 (CTCAE v5.0) requiring IV antibiotics, antivirals, or antifungals. 8. Patients with evidence or history of bleeding diathesis. Any haemorrhage or bleeding event ≥ CTCAE Grade 3 within 4 weeks prior to the start of study treatment. 9. Active primary immunodeficiency, known human immunodeficiency virus (HIV) infection, or active hepatitis B or C infection. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA. 10. History of (non-infectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening. 11. Lung criteria: 1. Lung-specific intercurrent clinically significant illnesses including, but not limited to, any underlying pulmonary disorder (e.g. pulmonary emboli within three months before study registration, severe asthma, severe COPD, restrictive lung disease, pleural effusion, etc.) 2

Inclusion Criteria: * Patients with high risk primary or recurrent breast cancer * Non pregnant women \> 18 years * Not receiving active treatment of other cancer types. * Eastern Cooperative Oncology Group (ECOG) status 0-2. Exclusion Criteria: * Pregnant woman * Males * Age under 18 * Patients receiving active treatment for other cancers * Poor general conditipon (ECOG 3 or higher)

Inclusion Criteria: * Post-menopausal women with ER+ breast cancer. * Metastatic or locoregional recurrence not amenable to treatment with curative * intent. * Received ≥1 prior line of endocrine-based therapy (e.g., including tamoxifen, aromatase inhibitors, fulvestrant, or combinations) in the advanced/metastatic setting Exclusion Criteria: * During the study Treatment Phase with 17b-estradiol, no concurrent anti-cancer therapies are allowed with the following exceptions: * Exception: Trastuzumab is allowed for the treatment of subjects with a history of HER2+ disease, and will be used at the physician's discretion. * Exception: Anti-resorptive bone therapies (e.g., bisphosphonates, denosumab) are permitted. * Any investigational cancer therapy in the last 3 weeks. * Known CNS disease, unless clinically stable for ≥ 3 months. * History of any of the following: * Deep venous thrombosis. * Pulmonary embolism. * Stroke. * Acute myocardial infarction. * Congestive heart failure. * Previous malignancy not treated with curative intent, or with an estimated recurrence risk ≥30%.

Inclusion Criteria: * Subject Eligibility Criteria 1. Diagnosis of IIH by modified Dandy criteria about for more than 2 months 2. Lumbar puncture opening pressure ≥250 mmH₂O within 6 weeks before enrollment 3. Normal cerebrospinal fluid (CSF) composition 4. Neuroimaging showing normal brain parenchyma without hydrocephalus, mass, or any structural lesion and no evidence of meningeal enhancement on CT or MRI 5. Localized venous sinus stenosis (VSS) with stenotic degree ≥ 50% on DSA, and pressure gradient across stenosis ≥ 8 mmHg 6. Patients or their relatives signed written informed consent * Ophthalmic Eligibility Criteria: 1. At least one eye had the presence of papilledema 2. At least one eye of visual field loss: PMD ranging from - 2dB and below; decreased visual function on automated perimetry was reproducible with a false-positive rate of no more than 15% 3. Visual acuity above 20 / 200 (≥ 39 letters) Exclusion Criteria: * Subject Exclusion Criteria 1. Previous surgery for IIH, including optic nerve sheath fenestration (ONSF), CSF shunting, decompressive craniectomy or venous sinus stenting 2. Progressive or rapid visual loss needed urgent surgical intervention; if delay\>24-48 h consider interim lumbar drain (for rapid visual loss only).Surgical options to consider: CSF diversion or optic nerve sheath fenestration 3. Visual loss due to other etiologies (eg, retinal drusen, retinal and optic neuropathy, cataracts, etc) 4. Other condition requiring the use of diuretics, steroids or other drugs to reduce intracranial pressure 5. DSA showed diffused venous sinus stenosis, cortical or deep vein stenosis 6. A history of severe thyroid disease and iodine allergy 7. Pregnant or lactating women 8. Severe cardiopulmonary, liver or kidney failure 9. Known hereditary or acquired haemorrhagic diathesis 10. Known hereditary or acquired thrombophilia 11. Platelet counts or coagulation abnormality 12. Major surgery or severe trauma or any traumatic brain injury within the previous 14 days 13. A history of cerebral hemorrhage, arteriovenous malformation, intracranial aneurysm or tumor 14. Other life threatening illness (eg, advanced cancer) likely to lead to death within a few months; the physical, psychological and social status of patients may affect follow-up (eg, drug addiction, advanced malignant disease, no telephone, no family, etc); cannot tolerate general anesthesia 15. Increased intracranial pressure due to other secondary factors * Ophthalmic Exclusion Criteria: 1. Current intraocular pressure \> 28mmHg or previous intraocular pressure \> 30mmHg 2. Refractive error spherical power greater than -6.0D or +6.0D and astigmatism greater than 3.0D, except for the following cases: 1. Myopia of - 6.0D to - 8.0D with the following: 1)There was no myopia related disease that can lead to decreased vision under the eyeground microscope (eg, scleral staphyloma, retinal thinning at the posterior pole, and moderate to severe disc tilt); 2) The patient wore contact lenses of appropriate degree for all visual field examinations. 2. Hyperopia of +6.0D to +8.0D with the following: 1) The presence of a well characterized peri optic disc edematous halo, as opposed to crowded small optic discs or other features of decreased visual acuity associated with hyperopic changes, was at the discretion of the site investigator or reading center leader (or his designee); 2) The patient wore contact lenses of appropriate degree for all visual field examinations. 3. Examination visible or past medical history known to have large optic disc drusen (persistent optic disc edema can present with small optic disc drusen, as low numbers are acceptable for inclusion and to be determined by the investigator to be unrelated to vision loss)

Inclusion Criteria: 1. \- Premenopausal patients candidate to start adjuvant hormone therapy after breast cancer surgery 2. \- Age \>18 years 3. \- No previous hormonal treatment 4. \- Written informed consent Exclusion Criteria: 1- Patient's inability to provide written informed consent 2 - Stage IV disease

Inclusion Criteria: 1. Histological confirmed invasive primary triple negative breast cancer≥15 mm) with any node status. 2. Age ≥18 years Triple Negative subtype is defined below: 1. Hormone receptor status: the invasive tumour shall be ER- and progesterone receptor (PR) -negative \[staining present in \<10% by immunohistochemistry (IHC)\]. 2. HER2 status: the invasive tumour shall be Human Epidermal growth factor Receptor (HER) 2-negative by the American Society of Clinical Oncology (ASCO) / College of American Pathologists (CAP) guidelines 3. No previous systemic treatment for TNBC 4. No concurrent anti-cancer treatment. Treatment with Bisphosphonates may continue. 5. Eastern Cooperative Oncology Group (ECOG) performance status 0-1 6. Normal organ function as defined below: 1. absolute white blood cell count ≥1.5 x 109/L 2. platelets ≥100 x 109/L 3. haemoglobin ≥90g/dL 4. total bilirubin ≤1.5 x institutional upper normal limit (UNL)/dL (≤ 3 x UNL for patients with Gilbert´s syndrome) 5. ASAT, ALAT, GGT and alkaline phosphatase levels \< 1.5 × institutional UNL. 6. albumin \>2.5mg/dL 7. Creatinine \< 110 μmol/L 8. T3, T4 and TSH (only patients with previous thyroid dysfunction) 7. Patients of childbearing potential must have a negative serum or urine pregnancy test within 8 days prior to start of imatinib treatment.. Female patients of childbearing potential must agree to usecontraceptive methods with a failure rate below 1% per year during the study treatment and at least 90 days after the last dose of imatinib. 8. Patients must be able to take (swallow) an oral medication. 9. Patients must be capable to understand and comply with the protocol and has signed the informed consent. Exclusion Criteria: 1. Patients suitable for neoadjuvant treatment. 2. Concomitant treatment for breast cancer within 14 days before registration. 3. Unable to adhere to the study procedures. 4. Evidence of any other medical conditions (such as psychiatric illness, infectious diseases, neurological conditions, physical examination or laboratory findings) that may interfere with the planned treatment or affect patient compliance. 5. Pregnancy and breast-feeding. 6. Concurrent malignancy requiring therapy (excluding non-invasive carcinoma or carcinoma in situ). 7. Known human immunodeficiency virus (HIV) positivity. 8. Known active Hepatitis B or Hepatitis C

Inclusion Criteria: 1. Is aged 18 or older 2. Is receiving prenatal services within the U.S 3. Is between 12-32 weeks pregnant 4. Speaks and understand English well enough to understand questionnaires when they are read aloud 5. Has access to a telephone through owning one, a relative/friend, or an agency 6. Is willing and able to provide the name and contact information of at least two locator persons Exclusion Criteria: 1. Has a current major depressive episode 2. Has current or past diagnosis of a bipolar disorder or a psychotic disorder